SLN
Silence Therapeutics PLC
NASDAQ: SLN · HEALTHCARE · BIOTECHNOLOGY
$7.31
+2.81% today
Updated 2026-04-30
Market cap
$363.70M
P/E ratio
—
P/S ratio
650.63x
EPS (TTM)
$-1.89
Dividend yield
—
52W range
$4 – $8
Volume
0.4M
Silence Therapeutics PLC (SLN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-37,150.00%
ROE
-90.30%
ROA
-30.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.95M | $-3.83M | 100.00% | -219.21% | -196.51% |
| 2007 | $4.05M | $-5.11M | -19.67% | -143.02% | -126.22% |
| 2008 | $2.21M | $-7.43M | -203.85% | -352.74% | -336.58% |
| 2009 | $1.72M | $-7.47M | -194.43% | -438.42% | -433.60% |
| 2010 | $2.37M | $-8.79M | -146.03% | -365.93% | -371.72% |
| 2011 | $694000.00 | $-5.74M | -384.29% | -833.72% | -826.66% |
| 2012 | $163000.00 | $-26.28M | -1,972.39% | -16,143.56% | -16,125.15% |
| 2013 | $117000.00 | $-9.00M | -4,727.35% | -7,753.85% | -7,694.02% |
| 2014 | $15000.00 | $-11.09M | -59,126.67% | -80,846.67% | -73,920.00% |
| 2015 | — | $-6.64M | — | — | — |
| 2016 | $770000.00 | $-8.44M | -1,031.30% | -1,546.23% | -1,096.10% |
| 2017 | $16000.00 | $-1.62M | -49,543.75% | -89,943.75% | -10,112.50% |
| 2018 | $0.00 | $-18.41M | — | — | — |
| 2019 | $244000.00 | $-19.58M | 100.00% | -9,317.21% | -8,025.41% |
| 2020 | $5.48M | $-32.55M | 31.34% | -654.26% | -594.03% |
| 2021 | $12.41M | $-39.41M | 39.94% | -369.02% | -317.44% |
| 2022 | $21.66M | $-50.33M | 37.83% | -281.87% | -232.44% |
| 2023 | $25.38M | $-43.27M | 59.34% | -195.48% | -170.51% |
| 2024 | $43.26M | $-45.31M | 72.70% | -146.38% | -104.74% |
| 2025 | $559000.00 | $-88.61M | 61.54% | -14,755.33% | -15,851.88% |